leading the future of drug delivery and pharmaceutical innovation

pioneering advances in drug delivery systems

The pharmaceutical landscape is undergoing a transformation, driven by the demand for enhanced drug efficacy, improved patient compliance, and streamlined manufacturing processes.

As an industry leader, Aurorium is at the forefront of this evolution, leveraging cutting-edge research and development to offer tailored solutions for biopharmaceuticals, drug delivery, and controlled-release formulations.

strategic investments for a better tomorrow

To strengthen its position as a global innovator, Aurorium has made significant investments in expanding its drug delivery capabilities.

These investments include increased manufacturing capacity for pharmaceutical-grade excipients and controlled-release technologies, ensuring a more reliable, scalable, and efficient supply chain for pharmaceutical companies.

Jenny Titova, Strategic Marketing Manager - Pharmaceuticals, stated:
“This investment underscores Aurorium’s strategic focus on life sciences. It reinforces our leading position in North America and strengthens our supply capabilities globally as we continue to expand with our customer base.”

Additional capacity has also been added for the manufacture of NaOH Pellets, also known as caustic pellets.

• Sodium Hydroxide is used by the large molecule biologics industry in both the upstream (cell culture) and downstream(separation & purification and fill & finish) processes.
• Potassium Hydroxide is used in soft gel capsules to enhance the solubility of acidic active pharmaceutical ingredients (APIs).

innovative solutions for drug delivery

Aurorium’s comprehensive portfolio of specialty pharmaceutical solutions is designed to:

1. optimize drug delivery systems for improved therapeutic efficacy.
2. ensure patient safety and convenience through advanced controlled-release technologies.
3. enhance bioavailability and stability in pharmaceutical formulations.

key advancements include:

• formulation development: collaborating with pharmaceutical manufacturers to develop customized drug formulations that improve bioavailability, stability, and controlled release.
• controlled release systems: technologies that enable sustained drug release, enhancing patient compliance and reducing dosing frequency.
• excipient solutions: a broad selection of functional plasticizers, buffers, coating agents, and vaccine adjuvants, crucial for pharmaceutical formulation and delivery.
• thought leadership: shaping the future of biopharmaceutical innovation

Aurorium’s continued expansion and investment in pharmaceutical solutions solidify its role as a thought leader in the industry.

Dr. Steve Tattum, Vice President of Aurorium Specialty Solutions, emphasized:
“these capital investments follow multiple strategic acquisitions, expanding our Healthcare portfolio and emphasizing our commitment to the global pharmaceutical market. The continued growth will strengthen our global position in the biopharmaceutical markets as a reliable and dedicated partner.”

a commitment to excellence and sustainability

Aurorium is committed to maintaining the highest regulatory standards across its manufacturing facilities, ensuring consistency, quality, and safety.

As a Responsible Care® company, Aurorium continues to develop sustainable, high-performance materials that contribute to global health and wellness.

advancing drug delivery for the next generation

Aurorium is dedicated to advancing pharmaceutical innovation through continuous research, strategic partnerships, and scalable manufacturing.

By focusing on controlled-release formulations and enhanced biopharmaceutical solutions, Aurorium is driving the future of drug delivery and patient-centric medicine.